Publications by authors named "C Bocelli-Tyndall"
Article Synopsis
- The study investigates the effects of fibroblast growth factor 2 (FGF2) on the characteristics of human bone marrow mesenchymal stromal cells (hBM-MSC), particularly focusing on key osteoimmunological markers.
- The researchers utilized methods like RT-PCR and flow cytometry to analyze the expression of markers RANK, RANKL, OPG, and HLA-DR in hBM-MSC under specific culture conditions, alongside examining the impact of inflammatory cytokines IL1β and IFNγ.
- The findings reveal that OPG is consistently expressed regardless of FGF2, while RANKL expression relies on FGF2, and that various regulatory mechanisms affect the expression of HLA-DR, suggesting the
Mesenchymal stem/stromal cells (MSC) are multipotent precursors endowed with the ability to home to primary and metastatic tumor sites, where they can integrate into the tumor-associated stroma. However, molecular mechanisms and outcome of their interaction with cancer cells have not been fully clarified. In this study, we investigated the effects mediated by bone marrow-derived MSC on human colorectal cancer (CRC) cells in vitro and in vivo.
View Article and Find Full Text PDFFollowing the coordinated efforts of five established scientific organizations, this report describes the "novel cellular therapy" activity (i.e., cellular treatments excluding hematopoietic stem cells [HSC] for the reconstitution of hematopoiesis) in Europe for the year 2011.
View Article and Find Full Text PDFMesenchymal stem cells (MSCs) have attracted much interest in oncology since they exhibit marked tropism for the tumor microenvironment and support or suppress malignant cell growth depending on the tumor model tested. The aim of this study was to investigate the role of MSCs in the control of the growth of neuroblastoma (NB), which is the second most common solid tumor in children. In vivo experiments showed that systemically administered MSCs, under our experimental conditions, did not home to tumor sites and did not affect tumor growth or survival.
View Article and Find Full Text PDFObjectives: To determine the clinical characteristics of simultaneous occurrence of antitopoisomerase (ATA) and anticentromere (ACA) autoantibodies in systemic sclerosis (SSc).
Methods: Data of patients (n=4,687) fulfilling the ACR criteria for SSc and followed in the EULAR Scleroderma Trials and Research (EUSTAR) cohort were analysed. Sera from patients with simultaneous ATA and ACA were reanalyzed centrally by indirect immunofluorescence, enzyme immunoassay, and immunoblot to confirm antibody status.